who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

How Elevance Health (ELV) makes money: Q3 2026 revenue breakdown

US GAAP, Q3 2026 · quarter ended 09/30/2026 · released Oct 21

Shareholders' net income

$1,365M

up 14.8% y/y

Total revenues

$51,429M

up 1.4% y/y

Next report

~ Jan 27

not announced yet

The quarter in brief

Total revenues rose 1.4% y⁠/⁠y to $51.43B with flat premiums and growth at CarelonRx; the benefit expense ratio improved 70 basis points to 90.6% and net investment income jumped to $1,037M from $625M; shareholders' net income rose 14.8% to $1,365M ($6.27 per diluted share vs $5.32).

Key growth driver: Net investment income less net losses on financial instruments (calculated) — the fastest-growing revenue line: $989, +59% y/y. · by the Q3 2026 report

How does Elevance Health make money?

Elevance Health brought in $51.4 billion of revenue in Q3 2026, up 1.4% year over year. The largest source was Premiums: $41.7 billion, or 81% of the total, followed by Product revenue ($6.45B, 13%) and Service fees ($2.28B, 4%); other lines add the remaining 2%. Net income for the quarter was $1.36 billion, up 14.8% year over year.

Revenue by source, Q3 2026
  • Premiums$41.7B · 81% · −0.2%
  • Product revenue$6.45B · 13% · +4.8%
  • Service fees$2.28B · 4% · +6.8%
  • Net investment income less net losses on financial instruments (calculated)$989M · 2% · +58.5%

Shares of $51.4B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.

All figures in $M.

Sankey diagram of ELV (Elevance Health) earnings report for Q3 2026: revenue, costs and profitPremiums$41,704 · −0.2%Product revenue$6,454 · +4.8%Service fees$2,282 · +6.8%Net investment income lessnet losses on financialinstruments (calculated)$989 · +58.5%Total revenues$51,429 · +1.4%Benefit expense$37,779 · −0.9%Cost of productssold$5,640 · +4.8%Operating expense$5,752 · +9.1%Interest expense$358 · +2.0%Amortization ofother intangibleassets$106 · −34.6%Income beforeincome taxexpense$1,794 · +27.6%3.5% marginIncome tax expense$451 · +106%25.1% effective rateNet loss (gain)attributable tononcontrolling interests$22 · +1000%Shareholders' net income$1,365 · +14.8%$6.27/sh · 2.7% margin
Sankey diagram of ELV (Elevance Health) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Premiums$41,704 · −0.2%
Product revenue$6,454 · +4.8%
Service fees$2,282 · +6.8%
Net investment income less net losses on financial instruments (calculated)$989 · +58.5%
Total revenues$51,429 · +1.4%
Benefit expense$37,779 · −0.9%
Cost of products sold$5,640 · +4.8%
Operating expense$5,752 · +9.1%
Interest expense$358 · +2.0%
Amortization of other intangible assets$106 · −34.6%
Income before income tax expense$1,794 · +27.6% · 3.5% margin
Income tax expense$451 · +106% · 25.1% effective rate
Net loss (gain) attributable to noncontrolling interests$22 · +1000%
Shareholders' net income$1,365 · +14.8% · $6.27/sh · 2.7% margin

Verdict: total revenues rose 1.4% y/y to $51.43B with flat premiums and growth at CarelonRx; the benefit expense ratio improved 70 basis points to 90.6% and net investment income jumped to $1,037M from $625M; shareholders' net income rose 14.8% to $1,365M ($6.27 per diluted share vs $5.32).

FY 2026 guidance raised: diluted EPS at least $22.00, adjusted diluted EPS (non-GAAP) at least $29.00, operating cash flow at least $6.5 billion; Q3 adjusted diluted EPS $6.99; $330 million of shares repurchased in the quarter and a $1.72 quarterly dividend paid.

Source and notation

Source: Elevance Health earnings release, 8-K EX-99 of 10/21/2026 (SEC EDGAR). Insurer layout: total revenues = premiums + net investment income + fees and other revenues + realized investment gains (losses), as reported; benefits, claims and expenses are deducted to reach pre-tax income. The income statement lines were taken from the release by hand; the program found every figure in the release text and checked the accounting identities and the chart balance; SEC XBRL for this quarter is not published yet, so the XBRL check is pending.

Open as an image: Elevance Health (ELV), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Elevance Health (ELV) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/elv. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/elv"><img src="https://whoreportstoday.com/t/elv/img/elevance-health-elv-earnings-sankey.png" alt="Elevance Health (ELV) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/elv">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/elv/img/elevance-health-elv-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/elv">Elevance Health (ELV) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Elevance Health, Inc. is an American health insurance company. · Text: Wikipedia, CC BY-SA 4.0, abridged

Prior to June 2022, Elevance Health was named Anthem, Inc. The company is the world's seventh largest healthcare company based on revenue. Its services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans through affiliated companies such as Anthem Blue Cross and Blue Shield, Anthem Blue Cross in California, Wellpoint, and Carelon. It is the largest for-profit managed health care company in the Blue Cross Blue Shield Association.

Company reports

Q3 2026latest breakdownTotal revenues rose 1.4% y/y to $51.43B with flat premiums and growth at CarelonRx
Q2 2026Earnings fell 16% y/y as medical costs in government programs keep climbing (benefit ratio 89.7%, +80 bp), but…

Company guidance

Same quarter a year ago (ended December 31, 2025): revenue $49.7B, EPS (GAAP) $2.56

How we calculate

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

ELV earnings history: past report dates

Oct 21, 2026 Wed6:01 ambefore market openSep 30, 2026$51.4B+1% y/y$6.27+18% y/y
Jul 15, 2026 Wed6:01 ambefore market openJun 30, 2026$50.5B+1% y/y$6.71−13% y/y
Apr 22, 2026 Wed6:02 ambefore market openMar 31, 2026$50.2B+3% y/y$8.00−17% y/y
Jan 28, 2026 Wed6:03 ambefore market openDec 31, 2025≈$49.7B+9% y/y≈$2.56+36% y/y
Oct 21, 2025 Tue6:01 ambefore market openSep 30, 2025$50.7B+12% y/y$5.32+22% y/y
Jul 17, 2025 Thu6:03 ambefore market openJun 30, 2025$49.8B+13% y/y$7.72−22% y/y
Apr 17, 2025 Thu10:24 amduring market hoursMar 31, 2025$48.9B+15% y/y$9.61+0% y/y
Jan 23, 2025 Thu6:03 ambefore market openDec 31, 2024≈$45.4B+7% y/y≈$1.88−49% y/y
Oct 17, 2024 Thu6:02 ambefore market openSep 30, 2024$45.1B+5% y/y$4.36−20% y/y
Jul 17, 2024 Wed6:09 ambefore market openJun 30, 2024$43.9B+0% y/y$9.85+26% y/y
Apr 18, 2024 Thu6:07 ambefore market openMar 31, 2024$42.6B+1% y/y$9.59+16% y/y
Jan 24, 2024 Wed6:04 ambefore market openDec 31, 2023≈$42.6B+7% y/y≈$3.68+2% y/y
Oct 18, 2023 Wed6:05 ambefore market openSep 30, 2023$42.8B+7% y/y$5.45−18% y/y
Jul 19, 2023 Wed6:04 ambefore market openJun 30, 2023$43.7B+13% y/y$7.79+16% y/y
Apr 19, 2023 Wed6:05 ambefore market openMar 31, 2023$42.2B+11% y/y$8.30+13% y/y
Show all 15 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Elevance Health: 15-year financials

2025199,1257,1995,6623,1741,529
2024177,0117,8625,9804,5521,508
2023171,3408,4995,9876,7651,395
2022156,5958,2835,8947,2471,229
2021138,6397,5596,1587,2771,104
2020121,8676,3604,5729,667954
2019104,2135,9994,8074,984818
201892,1055,4263,7502,619776
201790,0404,1753,8433,394705
201684,8634,8012,4702,686684
201579,1574,7532,5603,574657
201473,8744,4182,5702,655481
201371,0244,0012,4902,406448
201261,4973,6202,6562,200367
201160,7113,7822,6472,855358

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. Dividends paid and share buybacks are actual annual cash payments from the cash flow statement, shown as positive cash outflows. Payments to noncontrolling interests and share-compensation withholding taxes are excluded. New values require three checks against issuer documents; unreviewed data is a dash and confirmed absence of payment is 0. Buybacks appear only when at least one reviewed payment exists in fifteen years. Updated after annual filings and document review. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Elevance Health: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
2025121,49443,88232,0469,49163,00141,035
2024116,88941,31531,2328,28858,94240,581
2023108,92839,30625,1206,52660,02941,791
2022102,75536,24324,1147,38755,61739,696
202197,45636,09523,0314,88051,12234,885
202086,61533,19920,0355,74145,75129,453
201977,45331,72820,0854,93739,03323,532
201871,57128,54119,2113,93434,32121,965
201770,54026,50319,9323,60936,26323,356
201665,08325,10115,7274,07534,31521,294
201561,71823,04515,8652,11330,86219,093
201461,67624,25115,0442,15231,94818,753
201359,57524,76514,4921,58229,74616,352
201258,95523,80314,9782,47529,34815,995
201152,16323,2889,8402,20227,09715,899

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated7,5124,206+3,306
· incl. D&A (non-cash add-back)depreciation & amortization1,0831,140
· incl. stock-based comp (non-cash)share-based compensation210246
Capexpurchases of property & equipment−789−823+34
Free cash flow ≈operating cash flow − capex6,7233,383+3,340
Investing activities, netcapex, acquisitions, securities−3,470−1,808−1,662
· incl. acquisitionsbusinesses net of cash acquired255−53
Financing activities, netdebt, buybacks, dividends−3,171−1,974−1,197
· incl. buybacksrepurchases of common stock−1,688−2,134+446
· incl. dividends paid−1,122−1,152+30
FX effect on cash−141−15
Net change in cash857425+432
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Bank or insurer: CAPEX and FCF do not apply to this business model — “—”.

Shareholders’ equity at Sep 30, 2026: $44.7B (35% of total assets). Compare with other S&P 500 companies →

Corporate governance

2/2good

  • Feb 20262025 10-K cover: a single class — Common Stock $0.01 (NYSE: ELV). sec.gov ↗
  • Feb 2026Diluted share count −11.7% over 2020–2025; buybacks of $2.6–2.9B in 2023–2025; SBC 0.14% of revenue (XBRL). data.sec.gov ↗
2 more facts and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Feb 2026Per-share dividend $3.80 (2020) → $5.92 (2023); a quarterly dividend of $1.72 was declared in February 2026. sec.gov ↗
  • Feb 2026The Litigation and Regulatory Proceedings section of the 2025 10-K lists BCBS antitrust cases and a DOJ suit over Medicare risk adjustment; no settled shareholder disclosure suits or SEC cases. sec.gov ↗

Scoring: 2.0 with no deductions = 2.0 (single share class, shares −11.7% over 5 years, dividend rising, 2025 class action unresolved, no SEC cases)

Share classes
Single class of common stock (10-K cover: Common Stock, NYSE).
Dilution
Diluted shares −11.7% over 2020–2025 on buybacks of $1.9–2.9B a year; SBC 0.14% of revenue.
Disclosure
Full 10-K/10-Q reporting.
Dividends
Dividend raised every year: $3.80 (2020) → $5.92 (2023) → $1.72 quarterly in 2026.
Lawsuits & regulators
Class action Miller v. Elevance (S.D. Ind., May 2025) over Medicaid cost guidance — unresolved → no deduction; the 10-K's litigation is antitrust (BCBS) and False Claims Act (not about disclosure to investors); no SEC cases.
Related parties
No material related-party transactions in the 2026 proxy.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies with revenue growth 10 years in a row · S&P 500 companies that paid dividends 10 years without a gap · S&P 500 companies shrinking their share count

Elevance Health (ELV) earnings: FAQ

How does Elevance Health make money?

Elevance Health brought in $51.4 billion of revenue in Q3 2026, up 1.4% year over year. The largest source was Premiums: $41.7 billion, or 81% of the total, followed by Product revenue ($6.45B, 13%) and Service fees ($2.28B, 4%); other lines add the remaining 2%. Net income for the quarter was $1.36 billion, up 14.8% year over year.

When is ELV's next earnings date?

We have not yet seen an announcement of the date from Elevance Health (ELV). Based on last year's report on Jan 28, 2026, the next report is expected around Jan 27, 2027.

What time does ELV report earnings?

Elevance Health usually reports before market open: its latest results release was filed with the SEC at 6:01 am ET on Oct 21, 2026.

When did ELV last report earnings?

Elevance Health reported Q3 2026 results on Oct 21, 2026.

Where can I find Elevance Health's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to ELV's filings; this page breaks the latest report down in a Sankey chart.

What was ELV's net income in Q3 2026?

Elevance Health reported net income of $1,365M for Q3 2026 (+14.8% year over year), under US GAAP.

Does Elevance Health pay dividends?

Yes. In 2025, Elevance Health paid $1,529M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.

How has Elevance Health's revenue changed since 2011?

Per its 10-K filings, revenue grew 3.3x: $60,711M in 2011 and $199,125M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: EW · Q2 2026 · GEHC · Q3 2026 · GILD · Q3 2026 · HCA · Q3 2026 · HSIC · Q3 2026 · HUM · Q2 2026 · IDXX · Q3 2026 · ILMN · Q3 2026 · INCY · Q2 2026 · IQV · Q3 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy